Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Trial Profile

Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2018

At a glance

  • Drugs Palbociclib (Primary) ; Cetuximab; Cisplatin
  • Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms Los Tres Paso
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 May 2018 According to the Pfizer media release, results from this trial will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2018.
    • 30 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top